Jim Cramer looks at what to do with Eli Lilly, AMD shares after their big slides on earnings

  • 📰 CNBC
  • ⏱ Reading Time:
  • 23 sec. here
  • 25 min. at publisher
  • 📊 Quality Score:
  • News: 92%
  • Publisher: 72%

NVIDIA Corp أخبار

Earnings,Morning Meeting Recaps,Jim Cramer

The Investing Club holds its 'Morning Meeting' every weekday at 10:20 a.m. ET.

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Wednesday's key moments. 1. Stocks were higher Wednesday as big tech drove gains and bond yields remained tame. Earnings were keeping investors on their toes with more than half of all S & P 500 companies having reported third-quarter results already.

Shares of giant Eli Lilly were sinking more than 10% when the Morning Meeting was being recorded following Wednesday's before-the-bell sales and earnings misses for the third quarter and guidance cut. Jim is inclined to see the drop as a buying opportunity. The Club is restricted from buying Lilly because Jim mentioned on it TV. Lilly shares later trimmed those losses. GE Healthcare , meanwhile, also reported Wednesday morning.

لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 12. in EG
 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.

مصر أحدث الأخبار, مصر عناوين

Similar News:يمكنك أيضًا قراءة قصص إخبارية مشابهة لهذه التي قمنا بجمعها من مصادر إخبارية أخرى.

Eli Lilly and Company announce $4.5 billion investment in Lebanon LEAP district facilityOn Wednesday, Eli Lilly and Company announced a $4.5 billion investment into a new 'first of its kind' facility in Lebanon's LEAP district.
مصدر: wrtv - 🏆 598. / 51 اقرأ أكثر »

Stocks making the biggest moves premarket: Eli Lilly, Caterpillar, VinFast, Alphabet and moreThese are the stocks posting the largest moves in premarket trading.
مصدر: CNBC - 🏆 12. / 72 اقرأ أكثر »

Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings missEli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker on Wednesday chopped a few dollars off its earnings guidance for the year after raising that forecast well beyond analyst expectations in previous quarters.
مصدر: AP - 🏆 728. / 51 اقرأ أكثر »